Evolocumab in Patients With ST Elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study
Latest Information Update: 19 Nov 2024
At a glance
- Drugs Evolocumab (Primary)
- Indications Acute coronary syndromes; Dyslipidaemias
- Focus Therapeutic Use
- Acronyms EVACS II
Most Recent Events
- 15 Nov 2024 Status changed from active, no longer recruiting to completed.
- 08 May 2024 Planned End Date changed from 25 Apr 2024 to 25 Oct 2024.
- 08 May 2024 Planned primary completion date changed from 25 Apr 2024 to 25 Oct 2024.